Related Experiment Video
Updated: Nov 5, 2025
Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids
Published on: June 8, 2019
Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype
Jing Ma1, Xiaofei Ai2, Jinhuan Wang3
1Department of Hematology and Blood and Marrow Transplantation, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Huan-Hu-Xi Road, Ti-Yuan-Bei, Hexi District, Tianjin, 300060, China.
Multiplex ligation-dependent probe amplification (MLPA) detects chromosomal abnormalities in myelodysplastic syndrome (MDS) patients with normal karyotypes. This improves prognostication and guides individualized therapy for better patient outcomes.
Area of Science:
- Hematology
- Cytogenetics
- Molecular Diagnostics
Background:
- Chromosomal abnormalities are crucial for myelodysplastic syndrome (MDS) classification and prognosis.
- Over 50% of low-risk MDS patients present with a normal karyotype, complicating risk stratification.
- Multiplex ligation-dependent probe amplification (MLPA) is a robust method for detecting cytogenetic aberrations.
Purpose of the Study:
- To evaluate MLPA's utility in characterizing MDS patients with normal or undetectable karyotypes via conventional methods.
- To assess the prognostic impact of MLPA-detected aberrations in this patient subset.
- To determine if MLPA can refine individualized therapy strategies for MDS.
Main Methods:
- Analysis of 144 MDS patient samples with normal or undetectable karyotypes by standard chromosome banding.
- Parallel comparison of these samples using fluorescence in situ hybridization (FISH) and MLPA.
- Correlation of MLPA findings with overall survival (OS) data.
Main Results:
- MLPA identified copy number changes in 16.7% of the 144 analyzed MDS patients.
- A significant difference in overall survival was observed between MLPA-confirmed normal karyotype and aberrant karyotype cohorts (p=0.0071).
- Patients with karyotypes undetectable by standard methods showed inferior outcomes.
Conclusions:
- MLPA effectively clarifies cytogenetic status in MDS patients with normal or undetectable karyotypes.
- MLPA provides valuable prognostic information beyond conventional karyotyping.
- Enhanced cytogenetic characterization via MLPA can facilitate individualized therapeutic approaches in MDS.
